Article Text

PDF
New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor α antagonists
  1. S Kary1,*,
  2. M Worm2,*,
  3. H Audring2,
  4. D Huscher3,
  5. M Renelt4,
  6. H Sörensen5,
  7. E Ständer6,
  8. U Maaß7,
  9. H Lee2,
  10. W Sterry2,
  11. G-R Burmester1
  1. 1Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany
  2. 2Department of Dermatology and Allergy, Charité-University Medicine Berlin, Berlin, Germany
  3. 3Epidemiology Unit, German Rheumatology Research Centre, Berlin, Germany
  4. 4Rheumatology Clinic, Sendenhorst, Germany
  5. 5Rheumatologist, Berlin, Germany
  6. 6Rheumatology/Diabetes Unit, Hospital Schwerin, Germany
  7. 7Rheumatology Centre, Suedstadt Klinikum, Rostock, Germany
  1. Correspondence to:
    Professor G –R Burmester
    Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Schumannstr 20–21, 10117 Berlin, Germany; gerd.burmester{at}charite.de

Abstract

Background: Blockage of tumour necrosis factor α (TNFα) is highly effective in rheumatic diseases, especially in rheumatoid arthritis (RA), ankylosing spondylitis, and psoriatic arthritis. Furthermore, TNFα antagonists have also been shown to significantly reduce psoriatic skin lesions.

Case reports: A series of nine patients with RA who were treated with different types of TNFα antagonists and who unexpectedly developed either a new onset or an exacerbation of psoriatic skin lesions are reported

  • LEF, leflunomide
  • MTX, methotrexate
  • RA, rheumatoid arthritis
  • TNFα, tumour necrosis factor α
  • psoriasis
  • tumour necrosis factor antagonists
  • side effects
  • rheumatoid arthritis

Statistics from Altmetric.com

Footnotes

  • * S Kary and M Worm contributed equally to this article.

  • Published Online First 8 September 2005

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.